Popular terms

Antagonist topics
Antagonist
Recurrence
Proliferative Disorder
Proliferative
Antibodies
Progesterone
Dicyclomine
Scopolamine
Extracellular
Pharmaceutically Acceptable Salt
Metalloprotein
Nucleic Acids
Polynucleotide
Nucleic Acid
Monoclonal

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Antagonist patents



      

This page is updated frequently with new Antagonist-related patent applications.




Date/App# patent app List of recent Antagonist-related patents
05/19/16
20160138027 
 Treatment of diseases and conditions associated with dysregulation of mammalian target of rapamycin complex 1 (mtorc1) patent thumbnailTreatment of diseases and conditions associated with dysregulation of mammalian target of rapamycin complex 1 (mtorc1)
Compositions and methods for treating diseases and conditions associated with dysregulation of mammalian target of rapamycin complex 1 (mtorc1) are disclosed. The invention is based in part on the discovery that protein mediator of amino acid signaling to mtor (mortor) is involved in amino acid-induced translocation of mtorc1 to lysosomes where mortor forms a signaling complex with mtorc1, ragulator, and rag gtpases, which controls protein synthesis.
The Board Of Trustees Of The Leland Stanford Junior University


05/19/16
20160138022 
 Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response patent thumbnailImmune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response
The invention provides novel immune regulatory oligonucleotides (iro) as antagonist of tlrs and methods of use thereof. These iros have unique sequences that inhibit or suppress tlr-mediated signaling in response to a tlr ligand or tlr agonist.
Idera Pharmaceuticals, Inc.


05/19/16
20160137737 
 Integrin alpha-v beta8 neutralizing antibody patent thumbnailIntegrin alpha-v beta8 neutralizing antibody
The present invention relates to αvβ8 antagonists, anti-αvβ8 antibodies or immunoconjugates for reducing tgfβ activation in an individual. Further provided are compositions comprising one of the αvβ8 antagonists, anti-αvβ8 antibodies or immunoconjugates, methods for using the compositions, and related subject matter..
The Regents Of The University Of California


05/19/16
20160137717 
 Use of a vegf antagonist in treating choroidal neovascularisation patent thumbnailUse of a vegf antagonist in treating choroidal neovascularisation
The present invention relates to the use of a non-antibody vegf antagonist, in the treatment of choroidal neovascularisation secondary to diseases other than age-related macular degeneration and pathologic myopia.. .

05/19/16
20160137629 
 Compounds for binding to the platelet specific glycoprotein iib/iiia and their use for imaging of thrombi patent thumbnailCompounds for binding to the platelet specific glycoprotein iib/iiia and their use for imaging of thrombi
The present invention relates to novel fluorine containing compounds, methods for their preparation, the intermediates of the synthesis, their use as diagnostic agents, especially for imaging of thrombi. The invention relates to positron emission tomography (pet) agents and associated precursor reagents, and methods for producing such radiolaveled agents for imaging of thrombi in a mammalian body.
Piramal Imaging Sa


05/19/16
20160136248 
 Methods and materials for modulating deubiquitinases and ubiquitinated polypeptides patent thumbnailMethods and materials for modulating deubiquitinases and ubiquitinated polypeptides
This document relates to methods and materials involved in modulating deubiquitinases (e.g., usp10 polypeptides) and/or ubiquitinated polypeptides (e.g., tumor suppressor polypeptides or mutant versions of tumor suppressor polypeptides). For example, methods and materials for increasing deubiquitinase (e.g., a usp10 polypeptide) expression or activity, methods and materials for decreasing deubiquitinase (e.g., a usp10 polypeptide) expression or activity, methods and materials for stabilizing tumor suppressor polypeptides (e.g., wild-type p53 polypeptides), methods and materials for de-stabilizing mutant versions of tumor suppressor polypeptides (e.g., mutant p53 polypeptides), and methods and materials for reducing cancer cell proliferation, increasing cancer cell apoptosis, and/or treating cancer (e.g., cancers having reduced levels of wild-type p53 polypeptides or cancers having increased levels of mutant p53 polypeptides) are provided.
Mayo Foundation For Medical Education And Research


05/19/16
20160136245 
 Methods of treating pain using protein solutions patent thumbnailMethods of treating pain using protein solutions
Methods and compositions for treating pain in mammalian subjects are provided. The methods include obtaining blood or a fraction of blood from the subject, measuring a therapeutic indicator in the blood or in the fraction blood, and administering an anti-inflammatory composition to the subject if the therapeutic indicator is equal to or above a threshold level.

05/19/16
20160136196 
 Methods for treating pulmonary hypertension patent thumbnailMethods for treating pulmonary hypertension
The present invention relates to methods for treating or preventing pulmonary hypertension, reducing mortality in a subject experiencing pulmonary hypertension, or inhibiting adp-mediated vasoconstriction of pulmonary arteries in a subject, comprising administering to the subject an effective amount of a pharmaceutical composition comprising a reversible p2y12 receptor antagonist. Also provided are related medicaments, pharmaceutical compositions, and methods for preparing the medicaments..
The Medicines Company


05/19/16
20160136194 
 Pharmaceutical composition comprising a proton pump inhibitor and a prebiotic for the treatment of ulcerous lesions of the stomach and duodenum patent thumbnailPharmaceutical composition comprising a proton pump inhibitor and a prebiotic for the treatment of ulcerous lesions of the stomach and duodenum
A pharmaceutical composition including proton pump inhibitors and prebiotics is proposed for the treatment of gastric and duodenal ulcer, this allowing effective ulcer treatment and eradication of h. Pylori from the gastric and duodenal mucosa to be carried out without using wide-spectrum antibiotics.

05/19/16
20160136183 
 Pharmaceutical compositions for preventing glucocorticoid-induced corneal or skin thinning patent thumbnailPharmaceutical compositions for preventing glucocorticoid-induced corneal or skin thinning
The present invention relates to method and pharmaceutical compositions for preventing glucocorticoid-induced corneal or skin thinning. In particular, the present invention relates to a mineralocorticoid receptor antagonist for topical use in a method for preventing or reducing glucocorticoid-induced corneal or skin thinning in a subject in need thereof.
Assistance Publique-hopitaux De Paris (aphp)


05/19/16
20160136157 

Intranasal naloxone compositions and methods of making and using same


Disclosed herein are compositions containing an opioid antagonist such as naloxone and one or more pharmaceutically acceptable excipients. The compositions may be used for intranasal delivery of naloxone for the treatment of, for example, opioid overdose in an individual in need thereof.
Antiop, Inc.


05/19/16
20160136153 

Diversion-resistant opioid formulations


The present invention provides a composition comprising an opioid agonist, and a polymer-antagonist conjugate. The polymer-antagonist conjugate preferably does not hydrolyze upon administration to a patient, and does not bind to the opioid receptors.
Elysium Therapeutics, Inc.


05/19/16
20160136145 

Bitopic muscarinic agonists and antagonists and methods of synthesis and use thereof


Compositions for treating a condition associated with activity of a muscarinic receptor (e.g., one or more of m1, m2, m3, m4, m5) and for anesthetizing a subject include a bitopic muscarinic antagonist or agonist. A bitopic muscarinic antagonist named jb-d4 was discovered.
Barry University, Inc.


05/19/16
20160136119 

Dp2 antagonist and uses thereof


Described herein is the dp2 antagonist [2′-(3-benzyl-1-ethyl-ureidomethyl)-6-methoxy-4′-trifluoromethyl-biphenyl-3-yl]-acetic acid, or a pharmaceutically acceptable salt thereof. Also described are methods of preparing the dp2 antagonist, or a pharmaceutically acceptable salt thereof.
Brickell Biotech, Inc.


05/19/16
20160136079 

A3 adenosine receptor ligands for modulation of pigmentation


The present invention relates to compositions and methods for modulating melanin production, secretion and/or accumulation in human skin cells. In particular, the present invention relates to the use of a3 adenosine receptor antagonists in compositions and methods for the treatment and amelioration of hyper-pigmentation conditions and for the lightening of skin, and to the use of a3 adenosine receptor agonists in compositions and methods for the treatment and amelioration of hypo-pigmentation conditions and for the tanning of skin..
Oradin Pharmaceutical Ltd.


05/12/16
20160130337 

Methods for treating ocular diseases


A method is provided for reducing the treatment burden for patients who have an intraocular neovascular disorder, the method comprising administering a therapeutically effective amount of vegf antagonist on a dosing schedule that includes treatment intervals of 8 and/or 12 weeks.. .
Novartis Ag


05/12/16
20160130332 

Antibodies to human signal peptide-containing proteins


The invention provides a human signal peptide-containing proteins (sigp) and polynucleotides which identify and encode sigp. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists.
Incyte Corporation


05/12/16
20160130321 

Use of a vegf antagonist in treating macular edema


The present invention relates to the use of a non-antibody vegf antagonist in the treatment of macular edema secondary to diseases or conditions other than diabetes or retinal vein occlusion.. .

05/12/16
20160130320 

Modified chimeric polypeptides with improved pharmacokinetic properties


The present invention provides vegf antagonists with improved pharmacokinetic properties. According to certain embodiments, a fusion polypeptide capable of antagonizing vegf activity is provided comprising a modified extracellular ligand binding domain of a vegf receptor fused to a multimerizing component..
Regeneron Pharmaceuticals, Inc.


05/12/16
20160130318 

Interleukin 15 (il-15) antagonists and uses thereof for the treatment of autoimmune diseases and inflammatory diseases


The present relates to interleukin 15 (il-15) antagonists and uses thereof, in particular for the treatment of autoimmune diseases and inflammatory diseases. In particular, the present invention relates to an il-15 mutant polypeptide having the amino acid sequence as set forth in seq id no:1 wherein the leucine residue at position 45 is substituted by an aspartic acid residue, the asparagines residue at position 65 is substituted by a lysine residue and the leucine residue at position 69 is substituted by an arginine residue.
Universite D'angers


05/12/16
20160130273 

Process for making cgrp receptor antagonists


The invention encompasses a novel process for making piperidinone carboxamide indane and azainane derivatives, which are cgrp receptor antagonists useful for the treatment of migraine.. .
Merck Sharp & Dohme Corp.


05/12/16
20160130270 

Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives


The invention relates to fluorinated compounds and their use as integrin receptor antagonists. Novel fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives and pharmaceutically acceptable salts or solvates thereof and their use are described..
Scifluor Life Sciences, Inc.


05/12/16
20160130262 

N-substituted azetidine derivatives


The present invention relates to novel n-substituted azetidine derivatives<of the formula (i); wherein sermf is a selective estrogen receptor modilator fragment; x is no atom, o, s, ch2, carbonyl, n—r5; r1 is h, (c1-8)alkyl, (c3-8)cycloalkyl, (c3-6)heterocycloalkyl, (c2-6)alkenyl, (c2-6)alkynyl, (c1-4)alkylcarbonyl, (c1-4)alkoxy(c2-4)alkyl, (c3-6)cycloalkyl(c1-3)-alkyl, (c3-6)heterocycloalkyl(c1-3)alkyl, each independently optionally substituted with one or more halogen, nitrile, hydroxyl or (c1-2)alkyl; r5 is h, (c1-3)alkyl, optionally substituted with one or more fluorine; r17, r18 and r19 are independently of each other h, fluorine, nitrile or (c1-3)-alkyl, optionally substituted with one or more fluorine; or a prodrug, isotopically-labelled derivative or pharmaceutically acceptable salt thereof, >to pharmaceutical compositions comprising these compounds and to their use in therapy, in particular to their use for the prevention or treatment of ovulatory dysfunction, uterine cancer, endometrium cancer, ovarian cancer, endometriosis, osteoporosis, prostate cancer, benign prostatic hypertrophy, and breast cancer, in particular er-positive breast cancer, more in particular er-positive, hormone treatment-resistant breast cancer. Said n-substituted azetidine derivatives have estrogen receptor alpha (erα) antagonistic and—in certain embodiments—selective estrogen receptor downregulating (serd) activity in er-positive breast cancer cells..

05/12/16
20160130255 

Ethynyl derivatives


The present invention relates to ethynyl derivatives as metabotropic glutamate receptor antagonists (negative allosteric modulators) for use in the treatment of, e.g., anxiety and pain, depression, fragile-x syndrome, autism spectrum disorders, parkinson's disease, and gastroesophageal reflux disease (gerd).. .
Hoffmann-la Roche Inc.


05/12/16
20160130254 

Novel cyp17 inhibitors/antiandrogens


Wherein r1 to r8, a, b, z1, and z2 are as defined in the claims and pharmaceutically acceptable salts and esters thereof are disclosed. The compounds of formula (i) possess utility as androgen receptor antagonists (inhibitors) and/or cytochrome p450 monooxygenase 17α-hydroxylase/17,20-lyase (cyp17) inhibitors.

05/12/16
20160130232 

4-alkynyl imidazole derivative and medicine comprising same as active ingredient


There are provided 4-alkynylimidazole derivatives represented by the following general formula (i) or phamaceutically acceptable salts thereof; the derivatives have a superior ep4 receptor antagonistic action and are useful as pharmaceuticals for the treatment of diseases associated with the ep4 receptor, for example, as anti-inflammatory and/or analgesic drugs for inflammatory diseases and diseases that involve various kinds of pains, and further as pharmaceuticals for the treatment of immune diseases that result from inflammations as evoked by tissue destruction due to the activation of th1 cells and/or th17 cells:. .
Kaken Pharmaceutical Co., Ltd.


05/12/16
20160129080 

Treatment of polypoidal chroidal vasculopathy


Patients with polypoidal choroidal vasculopathy receive a combination of both (i) a photodynamic therapy, such as verteporfin and (ii) a non-antibody vegf antagonist.. .

05/12/16
20160128980 

Methods of treating ckd using predictors of fluid retention


The disclosure relates to methods of treating chronic kidney disease and diabetic nephropathy using predictors of fluid retention to minimize the risk of adverse events. The methods disclosed are particularly useful in treatments involving endothelin receptor antagonists, and more particularly, atrasentan and pharmaceutically acceptable salts thereof..
Abbvie Inc.


05/05/16
20160122434 

Antagonist of the btla/hvem interaction for use in therapy


The present invention relates to an antagonist of the btla/hvem interaction for use in therapy, wherein said antagonist increases the proliferation of vγ9vδ2 t cells.. .
Centre National De La Recherche Scientifique-cnrs


05/05/16
20160122389 

Peptides with antagonistic activities against natural cxcr4


A peptide effective in blocking the cxc-chemokine receptor 4 (cxcr4) mediated hiv-1 nl4-3 (x4-tropic) infection with an ic50 value of less than 50 μm.. .
Pharis Biotech Gmbh


05/05/16
20160121001 

Methods of inducing responsiveness to anti-angiogenic agent


The invention provides methods of inducing or improving responsiveness to a vegf antagonist to a subject or a subject population comprising administering an adenovirus comprising a nucleic acid construct comprising a fas-chimera gene operably linked to an endothelial cell-specific promoter and administering the vegf antagonist.. .
Vascular Biogenics Ltd.


05/05/16
20160120941 

Methods of using il-1 antagonists to treat alzheimer's disease


The invention provides methods of treating, inhibiting, or ameliorating a disease characterized by aberrant deposition of beta amyloid in a subject in need thereof, comprising administering to a subject a therapeutic amount of an interleukin 1 (il-1) antagonist, wherein the disease, or condition is treated, inhibited, or ameliorated, or wherein the onset or progression of the disease, or at least one symptom of the disease, is delayed. The il-1 antagonist is an il-1 trap, preferably comprising a sequence selected from the group consisting of seq id no: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, and 28 and capable of binding and inhibiting il-1.
Regeneron Pharmaceuticals, Inc.


05/05/16
20160120939 

Method for promoting bone growth using activin-actriia antagonists


In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density.. .
Acceleron Pharma Inc.


05/05/16
20160120877 

Pharmaceutical compositions for sustained delivery of benzodiazepine antagonists


The present invention relates to sustained release formulations of benzodiazepine antagonists and their use.. .

05/05/16
20160120861 

Compositions and methods for treating an arrhythmia with an opioid antagonist


Disclosed in certain embodiments is a method of treating an arrhythmia comprising administering to a patient in need thereof an effective amount of an opioid antagonist to treat the arrhythmia.. .
Purdue Pharma L.p.


04/28/16
20160116469 

Immunologically active polypeptide


Disclosed are immunomodulatory polypeptides that behave as weak tlr2 and tlr4 agonists and as potent competitive antagonists of natural pathogenic ligands for human and murine tlr2 and tlr4, that identify a subset of neutrophils in human peripheral blood leukocytes, and that elicit an unusual induced cytokine profile. Also disclosed are compositions comprising such polypeptides, compositions comprising antibodies that specifically bind to such polypeptides, and methods of using the same, including for treating sepsis or reducing the severity or likelihood of occurrence of sepsis, in cancer treatment, in the treatment of autoimmune diseases, in organ transplantation and for reducing graft rejection, for promoting fertility, and for identifying a neutrophil subset and/or other cellular subset including by flow cytometry.
Institute Of Arthritis Research, Llc


04/28/16
20160115228 

Antagonists of il-6 to prevent or treat thrombosis


The present invention is directed to therapeutic methods using il-6 antagonists such as antibodies and fragments thereof having binding specificity for il-6 to prevent or treat thrombosis in diseases associated with abnormal blood coagulation or fibrinolysis. In preferred embodiments these patients will comprise those exhibiting elevated d-dimer or other coagulation cascade related proteins and optionally will further exhibit elevated c reactive protein prior to treatment.
Alderbio Holdings Llc


04/28/16
20160113948 

System and diagnosis and treatment


This invention relates to a low cost rapid response diagnostic system to determine cortisol levels in patients selected as potential candidates for gcr (glucocorticoid receptor) antagonist therapy utilizing a gcr antagonist, such as org 34517. The rapid, sensitive, and inexpensive test can be used to determine patients who have non-normal cortisol production or disordered circadian rhythms as a method for selecting subjects for gcr antagonist therapy for whom it is likely to have beneficial and/or therapeutic effects, and can also be used to monitor changes in cortisol levels in response to treatment..
Pop Test Oncology Limited Liability Company


04/28/16
20160113928 

Heterocyclic compounds as hedgehog signaling pathway inhibitors


This invention relates to novel compounds of formula (i). The compounds of the invention are hedgehog pathway antagonists.
Redx Pharma Plc


04/28/16
20160113923 

Peripheral opioid receptor antagonists and uses thereof


Wherein x−, r1, and r2 are as defined herein, and compositions thereof.. .

04/28/16
20160113871 

Compositions for delivery of drug combinations


Compositions which comprise delivery vehicles having stably associated therewith non-antagonistic combinations of two or more agents, such as antineoplastic agents, are useful in achieving non-antagonistic effects when combinations of drugs are administered.. .
Celator Pharmaceuticals, Inc.


04/28/16
20160113286 

Lactobacillus plantarum strain for the control of fire blight


The present invention relates to the strain lactobacillus plantarum tc92, as well as to mutants thereof, and to the use of said strain as a pesticide for controlling fire blight in plants of the rosaceae family. Additional aspects of the invention relate to methods for producing the l.
Universitat De Girona


04/21/16
20160108116 

Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors


Disclosed herein are methods of treating benign, pre-cancerous, or non-metastatic tumors using an anti-vegf-specific antagonist. Also disclosed are methods of treating a subject at risk of developing benign, pre-cancerous, or non-metastatic tumors using an anti-vegf-specific antagonist.

04/21/16
20160106835 

Combination therapies for cancer


A novel combination comprising a b-raf inhibitor, particularly n-{3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide or a pharmaceutically acceptable salt thereof, the mek inhibitor n-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)6,8-dimethyl; -2,4,7-trioxo-3,4,6,7-tetrahydro-2h-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof, and a pd-1 antagonist; pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of mek and/or b-raf and/or immune modulation through pd-1 is beneficial, e.g., cancer.. .

04/21/16
20160106832 

Treatment of cancer with naltrexone


The present invention provides novel therapeutic applications of low dose naltrexone (ldn). Said applications have been determined in light of the discovery by the present inventors that naltrexone acts as an antagonist of toll-like receptor 9 (tlr9), an innate immune receptor which elicits the production of inflammatory cytokines when agonized.

04/21/16
20160106821 

Functional ghrelin receptor antagonism during pregnancy to prevent stress-associated mental illness in offspring and mothers


The invention relates to methods of protecting against elevated ghrelin levels in a fetus by antagonizing ghrelin or ghrelin receptor. The invention also encompasses methods of treating postpartum depression by administering ghrelin antagonists..

04/21/16
20160106803 

Use of tight junction antagonists in the treatment of acute lung injury and acute respiratory distress


The present application provides compositions and methods for treating acute lung injury and acute respiratory distress syndrome. The methods include administering one or more tight junction antagonists to the lung of a subject in need thereof..

04/21/16
20160106802 

Methods of diagnosing and treating asthma


The present invention provides materials and methods to diagnose asthma. In some embodiments, the present invention provides a method of diagnosing asthma by measuring the zonulin level of a subject.

04/21/16
20160106752 

Use of cb1 antagonists and/or inverse agonists for the preparation of drugs that increase motor neuron excitability


Use of a cb1 receptor antagonist and/or inverse agonist, preferably rimonabant, for the preparation of drugs useful for increasing motor neuron excitability in the cerebral cortex and/or in the brain stem and/or at the spinal level, as well as a method for increasing motor neuron excitability through the administration of a cb1 antagonist/ inverse agonist receptors, and to the use of a pharmaceutical composition which comprises a cb1 receptor antagonist and/or inverse agonist, preferably rimonabant, for increasing motor neuron excitability in the cerebral cortex and/or in the brain stem and/or at the spinal level.. .

04/21/16
20160106749 

Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists


The present invention provides treatment of fatty liver disease using a class of pyrimidinedione cyclohexyl compounds.. .

04/21/16
20160106726 

Pharmaceutical composition for treating alcohol dependency


A compound having an antagonistic action on the alpha1-noradrenergic receptors selected from prazosin, alfuzosin, terazosin and tamsulosin.. .

04/14/16
20160102311 

Protection against ionizing radiation and chemotherapy toxicity via latexin regulation


The present invention relates to methods for protecting against damage caused by radiation and/or chemotherapy, and methods for treating bone marrow damage by reducing/inhibiting latexin expression and/or latexin activity. The methods comprise administering to a subject in need thereof a pharmaceutical composition comprising an antagonist that reduces expression and/or activity of latexin, wherein latexin is a latexin polynucleotide variant and/or a latexin polypeptide variant that binds to the antagonist..

04/14/16
20160102145 

Antagonists of il-6 to prevent or treat cachexia, weakness, fatigue, and/or fever


The present invention is directed to therapeutic methods using antibodies and fragments thereof having binding specificity for il-6 to prevent or treat cachexia, fever, weakness and/or fatigue in a patient in need thereof. In preferred embodiments, the anti-il-6 antibodies will be humanized and/or will be aglycosylated.

04/14/16
20160102073 

2-hydroxymethyl-substituted orexin receptor antagonists


The present invention is directed to 2-hydroxymethyl compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved.

04/14/16
20160101152 

Use of a vegf antagonist to treat angiogenic eye disorders


The present invention provides methods for treating angiogenic eye disorders by sequentially administering multiple doses of a vegf antagonist to a patient. The methods of the present invention include the administration of multiple doses of a vegf antagonist to a patient at a frequency of once every 8 or more weeks.

04/14/16
20160101099 

H3 receptor antagonist for use in the treatment of alzheimer's disease


This disclosure relates to methods of using 2-(cyclohexylmethyl)-n-{2-[(2s)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide in a disease modifying therapy of alzheimer's disease, other tauopathies and related neurodegenerative diseases.. .

04/07/16
20160096899 

Methods for treating juvenile arthritis with anti-bile salt-stimulated lipase (bssl) antibodies


It provides methods and pharmaceutical compositions comprising antagonists to the protein bile salt-stimulated lipase (bssl) for the prevention, prophylaxis and treatment of inflammatory diseases, such as rheumatoid arthritis. It further relates to pharmaceutical compositions comprising bssl antagonists and their use in methods for the prevention, prophylaxis and treatment of inflammatory diseases, such as rheumatoid arthritis.
Lipum Ab


04/07/16
20160096803 

Crystal of pyrrole derivative and producing the same


The present invention provides a production intermediate of an atropisomer of a pyrrole derivative having excellent mineralocorticoid receptor antagonistic activity, a method for producing the same, and a crystal thereof. A method for producing an atropisomer of a pyrrole derivative including a step of resolving a compound represented by the following general formula (i) [wherein r1 represents a methyl group or a trifluoromethyl group, r2 represents a hydrogen atom or a c1-c3 alkoxy group, and n represents an integer selected from 1 to 3] into its atropisomers, characterized by using an optically active amine having a cinchonine skeletal formula, and a crystal of (s)-1-(2-hydroxyethyl)-4-methyl-n-[4-(methylsulfonyl)phenyl]-5-[2-(trifluoromethyl)phenyl]-1h-pyrrole-3-carboxamide..
Daiichi Sankyo Company, Limited


04/07/16
20160095897 

Par-4 antagonists for use in the treatment or prevention of influenza virus type a infections


The present invention provides methods and compositions (such as pharmaceutical compositions) comprising par4 antagonists for treating or preventing influenza virus type a infections, in particular h1n1 infection. Par4 antagonists may be combined with a par2 agonist or a par1 antagonist..
Universite Claude Bernard Lyon 1


04/07/16
20160095854 

Arylpiperazine opioid receptor antagonists


Where r, y3, r1, r2, r3, r4 and r5 are as defined herein.. .

04/07/16
20160095840 

Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist


Combinations of a muscarinic acetylcholine receptor antagonist and a beta 2 agonist for inhaled administration via the nose or mouth, and methods of using them are provided.. .
Glaxo Group Limited


03/31/16
20160090420 

Antagonist of the btla/hvem interaction for use in therapy


antagonist of the btla/hvem interaction for use in therapy the present invention relates to an antagonist of the btla/hvem interaction for use in therapy, wherein said antagonist increases the proliferation of vγ9vδ2 t cells.. .
Centre National De La Recherche Scintifique- Cnrs


03/31/16
20160090359 

Crystalline forms of an nk-1 antagonist


The present invention is related to crystalline forms of 2-(3,5-bis(trifluoromethyl)phenyl)-n,2-dimethyl-n-(6-(4-methylpiperazin-1-yl)-4-(o-tolyl)pyridin-3-yl)propanamide which is an nk-1 antagonist useful in the treatment of induced vomiting and other disorders.. .
Helsinn Healthcare Sa


03/31/16
20160090357 

Processes and intermediates in the preparation of c5ar antagonists


Intermediates and methods are provided for the preparation of selected c5ar antagonist compounds.. .
Chemocentryx, Inc.




Antagonist topics: Antagonist, Recurrence, Proliferative Disorder, Proliferative, Antibodies, Progesterone, Dicyclomine, Scopolamine, Extracellular, Pharmaceutically Acceptable Salt, Metalloprotein, Nucleic Acids, Polynucleotide, Nucleic Acid, Monoclonal

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Antagonist for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Antagonist with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.3376

4752

1 - 1 - 102